PCOS status linked to menopause age onset
March 28th 2024A recent regression model analysis unveils a 5% prolonged period to menopause in women with polycystic ovary syndrome, prompting further investigation into the condition's impact on reproductive health and the need for diverse longitudinal studies.
How genetic variables impact oral contraceptive use and VTE risk
March 27th 2024A comprehensive study delved into the interplay of polygenic and hereditary factors in venous thromboembolism risk among oral contraceptive users, shedding light on potential genetic markers for refined risk assessment and counseling.
FDA grants FTD to nipocalimab for treating FNAIT
March 26th 2024The FDA's Fast Track Designation for nipocalimab marks a significant step in addressing fetal neonatal alloimmune thrombocytopenia risk in pregnant patients, potentially revolutionizing treatment for this severe condition with unmet medical needs.
Study links low neighborhood food access to adverse birth outcomes
March 26th 2024A recent study highlighted the link between residence in low-income areas with limited food access during pregnancy and increased risks of lower birth weight and small for gestational age infants, urging further investigation into potential interventions for improved birth outcomes.
Exploring racial disparities in IVF outcomes
March 22nd 2024A recent study delves into how neighborhood socioeconomic factors affect miscarriage and live birth rates post- in vitro fertilization across diverse racial populations, not finding a correlation with neighborhood-level socioeconomic factors.
Global fertility rates plummet: Implications for future populations
March 21st 2024Recent research reveals a stark decline in global fertility rates, with 76% of countries projected to fall below the population-sustaining threshold by 2050, prompting urgent calls for policy interventions to address demographic shifts.
Dostarlimab shows significant survival benefits in endometrial cancer trial
March 21st 2024GlaxoSmithKline's phase 3 trial demonstrated promising overall and progression-free survival outcomes in patients with primary advanced or recurrent endometrial cancer, paving the way for potential FDA approval.
Study unveils maternal mortality tracking trends
March 20th 2024Delve into the implications of a study investigating maternal mortality tracking methods in the United States, as OB Hospitalist Group's Chief Medical Officer, Mark Simon, MD, highlights critical factors often overlooked and emphasizes collaborative care for preventing deaths.
Elinzanetant's efficacy for vasomotor symptoms confirmed in phase 3 trial
March 19th 2024Bayer's OASIS 3 trial affirmsed the safety and efficacy of elinzanetant in reducing moderate to severe vasomotor symptoms, bolstering confidence in its potential as a non-hormonal solution for menopause-related issues.